Management of acne: Canadian clinical practice guideline - PubMed (original) (raw)

Practice Guideline

. 2016 Feb 2;188(2):118-126.

doi: 10.1503/cmaj.140665. Epub 2015 Nov 16.

Affiliations

Practice Guideline

Management of acne: Canadian clinical practice guideline

Yuka Asai et al. CMAJ. 2016.

No abstract available

PubMed Disclaimer

Figures

Figure 1:

Figure 1:

Representative photos of acne categories. (A) Comedonal facial acne. (B) Moderate inflammatory facial acne. (C) Moderate inflammatory acne of the back. (D) Severe facial acne. (E) Severe inflammatory acne of the back.

Figure 2:

Figure 2:

Clinical treatment algorithm for acne. A complete list of recommendations is available in the full guideline (Appendix 4, available at

www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.140665/-/DC1

). BPO = benzoyl peroxide, clinda = clindamycin, dashed line = optional path. *Blue light and oral zinc may be considered for mild-to-moderate papulopustular acne (low strength of recommendation). †Best evidence is for adapalene and tazarotene. ‡Lower-quality evidence available for clindamycin–tretinoin gel. §Evaluate after 2–3 months. For women only. **Evaluate monthly for isotretinoin.

Similar articles

Cited by

References

    1. White GM. Recent findings in the epidemiologic evidence, classification, and subtypes of acne vulgaris. J Am Acad Dermatol 1998;39:S34–7. - PubMed
    1. Perkins AC, Cheng CE, Hillebrand GG, et al. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, continental Indian and African American women. J Eur Acad Dermatol Venereol 2011;25:1054–60. - PubMed
    1. Tan JK. The Canadian acne epidemiological survey: baseline demographics and interim analysis. J Am Acad Dermatol 2004;50:15. - PubMed
    1. James WD. Clinical practice. Acne. N Engl J Med 2005;352:1463–72. - PubMed
    1. Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 2003;63:1579–96. - PubMed

Publication types

MeSH terms

LinkOut - more resources